Etoposide

Catalog No.S1225 Synonyms: VP-16, VP-16213

Etoposide Chemical Structure

Molecular Weight(MW): 588.56

Etoposide is a semisynthetic derivative of podophyllotoxin, which inhibits DNA synthesis via topoisomerase II inhibition activity.

Size Price Stock Quantity  
In DMSO USD 91 In stock
USD 70 In stock
USD 280 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Cited by 111 Publications

Purity & Quality Control

Choose Selective Topoisomerase Inhibitors

Biological Activity

Description Etoposide is a semisynthetic derivative of podophyllotoxin, which inhibits DNA synthesis via topoisomerase II inhibition activity.
Targets
Topo II [2]
(Cell-free assay)
In vitro

Etoposide inhibits DNA synthesis by forming a complex with topoisomerase II and DNA, which induces breaks in double stranded DNA and prevents repair by topoisomerase II binding. Accumulated breaks in DNA prevent entry into the mitotic phase of cell division, and lead to cell death. Etoposide acts primarily in the G2 and S phases of the cell cycle. [1] Etoposide inhibits the growth of murine angiosarcoma cell line (ISOS-1) in a 5 days-period with IC50 of 0.25 μg/mL. Cell growth of normal murine microvascular endothelial cells (mECs) is less sensitive to Etoposide with IC50 of 10 μg/mL). [2] Etoposide treated for 6 hr inhibits colonies of tetraploid variant of the human leukemic lymphoblast line CCRF-CEM with IC50 of 0.6 μM. [3] Etoposide treated for 2 hr inhibits growth of human pancreatic cancer cell line Y1, Y3, Y5, Y19, YM. YS, and YT with IC50s of 300 μg/mL, 300 μg/mL, 300 μg/mL, 91 μg/mL, 0.68 μg/mL, 300 μg/mL, 300 μg/mL, and 260 μg/mL, respectively. [4] Etoposide exposed for 1 hr inhibits growth of human glioma cell lines CL5, G142, G152, G111, and G5 with IC50 of 8, 9, 9.8, 10, and 15.8 μg/mL respectively for 12 days. Under same condition, the IC90 value is attained in cell lines CL5, G152, G142, and G111 at 26, 27, 32, and 33 μg/mL. Etoposide inhibition of topoisomerase II is homogeneous for each cell. The average inhibition rates are 15%, 21.8%, 31.8%, 41.5%, and 49.5% for 1, 2, 4, 8, and 16 μg Etoposide, respectively. [5]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
Kelly MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Ml[4TWM2OD1yLkGy5qCKyrIkgJmwMlAyKM7:TR?= MmnyNlU6PjB{OEK=
KellyCis83 MmXIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mk\5TWM2OD1yLkG25qCKyrIkgJmwMlAzKM7:TR?= NGTtZ|QzPTl4MEK4Ni=>
SK-N-AS M3TXVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnnQTWM2OD1yLkK05qCKyrIkgJmwMlA{KM7:TR?= NHHQNFYzPTl4MEK4Ni=>
SK-N-ASCis24 NXe1dZRUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWfJR|UxRTBwNUhihKnDueLCiUCuNVEh|ryP NV[4bmRuOjV7NkCyPFI>
U87 MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3:yU|AuPTBizszN M2G1flQ5KGh? M3;FUoRm[3KnYYPld{Bk\WyuII\pZYJqdGm2eTD3bIlkcCClYX6gZoUh\W6qYX7j[YQh[nlic3nsbYJqdmmw NIfibIkzPTd3MEK3Ny=>
HCT116 MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NV[5U2xiOC53LUKuOUDPxE1? MmO5OFjDqGkEoB?= NIfyPFRKSzVyPUGuO|PDqMLzwrCwMlIyyqEQvF2= Mn\YNlU4PDZ5NkO=
HT-29 MmDES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFS5S2UxNjVvMj61JO69VQ>? NXjCcpNVPDkEoHlCpC=> NYqwUGlUUUN3ME23MlLDqMLzwrCxMlA1yqEQvF2= M4GyPFI2PzR4N{[z
Caco2 M13RXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2\BV|AvPS1{LkWg{txO Mn\XOFjDqGkEoB?= NFyxZ3FKSzVyPUeuNlbDqMLzwrCxMlY5yqEQvF2= NUSydWh{OjV5NE[3OlM>
COLO 205 NHjHO49Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYmwMlUuOi53IN88US=> MlfoOFjDqGkEoB?= MX7JR|UxRTFwNkJCpOKyyqByLkCyxsDPxE1? MXeyOVc1Pjd4Mx?=
SW480 NY\tOYZHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXuxTpUyOC53LUKuOUDPxE1? NVLzSoNoPDkEoHlCpC=> MnrFTWM2OD12LkmyxsDDucLiMD6zN:Kh|ryP MoK2NlU4PDZ5NkO=
HEK293T MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIi0dpUyNTVizszN MWC0POKhcMLi M4HpfGlEPTB;Mj60NuKhyrIEoECuNFXDqM7:TR?= NVTxRYZHOjV5NE[3OlM>
Hep3B  MmHXSpVv[3Srb36gRZN{[Xl? NFHTOmYyOCEQvF2= MnnPOFjDqGkEoB?= M2O4VpJm\HWlZYOgeIhmKGWwaHHuZ4lv\yCnZn\lZ5Qhd2ZiQl3QMVY> MnXMNlU3OzN3NkS=
Hep3B  MUHGeY5kfGmxbjDBd5NigQ>? MmfSNE4yNTFyIN88US=> Ml3JNlQhcA>? NHLmW21{fXCycnXzd4V{KHSqZTDlfJBz\XO|aX;uJI9nKGincHPp[IlvKG2UTlG= M3;kfVI2PjN|NU[0
HEK293 M1zZbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWXYU4k4UUN3ME23MlE1yqEEsdMgNE4{PsLizszN MUKyOVYxOzF{Mh?=
DU145 M1\LSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWTJR|UxRTJwMklCpOKyyqByLkC0xsDPxE1? MWGyOVYxOzF{Mh?=
HCT15 MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXTJR|UxRTBwOEJCpOKyyqByLkCxxsDPxE1? NHjOdJgzPTZyM{GyNi=>
T47D M4XINWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1X5TGlEPTB;Mz6xPOKhyrIEoECuNVHDqM7:TR?= MknBNlU3ODNzMkK=
SMMC-7721 MWLGeY5kfGmxbjDBd5NigQ>? NInmSIE1OCEQvF2= Mk[yOFghcA>? M1;EN2ROW09? MYfpcoR2[2W|IN8zTFJCYCCob3PpJIZwem2jdHnvci=> NVHObnZGOjV3NESzOlE>
MDA-MB-231 MmrES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NETteFY4OsLiaB?= M4\3fWlEPTB;MkGuNuKhyrIEoESuNuKh|ryP MVmyOVQ5PjJzOR?=
MCF-7 NH60OlZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXHHUGxmPzMEoHi= NWLX[mxUUUN3ME2xNE46yqEEsdMgNk4yyqEQvF2= M{LYVVI2PDh4MkG5
Jurkat MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mmm4O|LDqGh? NGPOS2JKSzVyPUGuNuKhyrIEoEGuOeKh|ryP MV[yOVQ5PjJzOR?=
HeLa NWPFT2RyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmrVO|LDqGh? NYDJVo1sUUN3ME2zMlnDqMLzwrCyMlPDqM7:TR?= NIHQZVIzPTR6NkKxPS=>
MCF7  M1Xpdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEfzZpk2NTFyMDFOwG0> NGq3NYY4KGR? M4XiVIlvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVz NVHXOW8zOjV2N{K2NVk>
K562 M1PpNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M13GblczyqCq NFXBbWdKSzVyPUCuNlnDqM7:TR?= NVPIUXNkOjV{OEK2OVM>
K/VP.5 MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlLKO|LDqGh? NWDneZFXUUN3ME20MlnDqM7:TR?= NXHZd5h7OjV{OEK2OVM>
SH-EP  M2TrOGZ2dmO2aX;uJGF{e2G7 NH34[JQzOMLizsznM41t NYC5O|JVOjUEoHi= M3jzR4lv[3KnYYPld{B1cGViZYjwdoV{e2mxbjDv[kBmdmSxZ3Xuc5V{KESHUGC= Mnm1NlUzPjF7OEG=
SCC25 M3Ozfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmfrNlTDqGh? MXvJR|UxRTR|LkRCpOKyyqBzLkGyxsDPxE1? NIn0[3UzPTJ{MEeyPS=>
CAL27 Mke4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4X1VVI1yqCq MVXJR|UxRTV{LkJCpOKyyqBzLkC5xsDPxE1? MkHMNlUzOjB5Mkm=
FaDu MkTNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUWyOOKhcA>? NGi0bYRKSzVyPUK1Mlg6yqEEsdMgNU4yO8LizszN NHTIbYszPTJ{MEeyPS=>
SCC25 MkjhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVi0POKhcA>? M3K4bWlEPTB;MkCuPFbDqMLzwrCxMlA4yqEQvF2= NIf2Xm0zPTJ{MEeyPS=>
CAL27 MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWm0POKhcA>? MYLJR|UxRTF6LkK0xsDDucLiMT6xOeKh|ryP MXKyOVIzODd{OR?=
FaDu NUC4ZpM{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUXWTWpPPDkEoHi= M4nvXGlEPTB;Nj60N:KhyrIEoEGuNVPDqM7:TR?= MUeyOVIzODd{OR?=
SCC25 MmT1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MY[3NuKhcA>? NWTH[5hMUUN3ME24MlQyyqEEsdMgNU4yOcLizszN NXnQbWRXOjV{MkC3Nlk>
CAL27 MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXjwOIl5PzMEoHi= MnztTWM2OD12LkK3xsDDucLiMT6xOOKh|ryP NEPXTnozPTJ{MEeyPS=>
FaDu MoqyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkXWO|LDqGh? MlqxTWM2OD13LkCyxsDDucLiMT6xOeKh|ryP NYn6dYR4OjV{MkC3Nlk>
MCF-7 NFW3NVVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mn;lOFjDqGkEoB?= MXrEUXNQ MXTJR|UxRTdwMtMgxtHDqDBwONMg{txO M3jEUFI2OjF4M{e4
T-47D NXHwPFJ5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVfMUYZyPDkEoHlCpC=> MXLEUXNQ MoW1TWM2OD15LkhCpOKyyqByLkhCpO69VQ>? M1LX[FI2OjF4M{e4
MDA-MB-231 M3LQVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2HxZlQ5yqCqwrC= NHLSdZJFVVOR M3XmWWlEPTB;MUKuPOKhyrIEoEGuNOKh|ryP Mlu2NlUzOTZ|N{i=
DU145 NXLJfZlDSXCxcITvd4l{KEG|c3H5 NGj4PW4yOC1zMECg{txO M1jBfVghcA>? NIixXIlFVVOR MV3pcoR2[2W|IHPlcIwh\GWjdHigd4lodmmoaXPhcpRtgSCrbjDhJJZmenlibH;3JINwdmOnboTyZZRqd25? M2G3VFI2OTR7Nkix
DU145 stem-like NH34fnRCeG:ydH;zbZMhSXO|YYm= MUOxNE0yODBizszN MWi4JIg> MV;EUXNQ MWDpcoR2[2W|IHPlcIwh\GWjdHigbY4h[SCmb4PlMYRmeGWwZHXueEBu[W6wZYK= MoG5NlUyPDl4OEG=
DU145 NEXS[XVHfW6ldHnvckBCe3OjeR?= M3rmeVExNTFyMDFOwG0> M4rWc|IhcA>? NV;ncW9HTE2VTx?= NXqwVWxRcW6lcnXhd4V{KHSqZTDwR2hMOSCneIDy[ZN{cW:wIHHu[EBl\WO{ZXHz[ZMhfGinIIDDTGsyKGW6cILld5Nqd25iaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ? MWSyOVE1QTZ6MR?=
DU145 stem-like MWDGeY5kfGmxbjDBd5NigQ>? NUPuOm9jOTBvMUCwJO69VQ>? NInl[XkzKGh? MnXzSG1UVw>? MUfpcoNz\WG|ZYOgeIhmKHCFSFuxJIV5eHKnc4Ppc44h[W6mIHTlZ5Jm[XOnczD0bIUheEOKS{Gg[ZhxemW|c3nvckBqdiCjIHTvd4Uu\GWyZX7k[Y51KG2jbn7ldi=> Mn\DNlUyPDl4OEG=
UW228-3 MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NX7rNWpUOC5yMT2zNFAh|ryP MVK0PEBp NXXONnlRTE2VTx?= M3jhRmlEPTB;MD65PeKh|ryP MlnlNlUyOTlzOEW=
NSCs MkLrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYrDNWxuOC5yMT2zNFAh|ryP NWTUNnF2PDhiaB?= MkftSG1UVw>? MoLWTWM2OD1yLkOtN:Kh|ryP NUDCWHNmOjVzMUmxPFU>
MKL-1  MmDTSpVv[3Srb36gRZN{[Xl? MlmxNVAuOTByMDDuUS=> NUPJXXBOPCCm M4jPeYlv\HWlZYOgeIhmKGmwZIXjeIlwdiCxZjDNTGMuUSCneIDy[ZN{cW:w NHvnZnozPTFzNke1OC=>
MCF7 EV NX6ye49MTnWwY4Tpc44hSXO|YYm= MYWxNE0yODBizszN M1S1RlLjiImq NV7zRm5ycW6mdXPld{Bxem:mdXP0bY9vKG:owrFOt2gzSVh? NUTLd5R1OjVyOEiyNFM>
MCF 7BMI1 NFLweGxHfW6ldHnvckBCe3OjeR?= MXWxNE0yODBizszN NWThbGFoOuLCiXi= NYi4dZBicW6mdXPld{Bxem:mdXP0bY9vKG:owrFOt2gzSVh? MoHpNlUxQDh{MEO=
MCF7 EV M1TNWWZ2dmO2aX;uJGF{e2G7 NWrTU3A2OTBvMUCwJO69VQ>? NHvEdIEz6oDLaB?= M1rmXmVVV1BiaX7keYNmeyCDVF2gZYN1cX[jdHnvci=> NGDseWszPTB6OEKwNy=>
MCF7 BMI1 NFTFU2hHfW6ldHnvckBCe3OjeR?= M1P2elExNTFyMDFOwG0> NW[wbIZQOuLCiXi= NVTTUHIyTVSRUDDpcoR2[2W|IFHUUUBi[3SrdnH0bY9v Ml;jNlUxQDh{MEO=
HepG2 NX;4eYhiT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVj5PHh{TE2VT9Mg MXzJR|UxRTNyLkG2xsDDucLiMD61NOKh|ryP MWeyOVA4QDNzMR?=
MOLT-3 MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3TMN2ROW00EoB?= MXTJR|UxRTBwMEWxxsDDucLiMD6wNFLDqM7:TR?= M{PHNVI2ODd6M{Gx
HT1080 M2HIemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4GxZlEuOTByIN88US=> MlOzOE8zPC92ODDo NUm3XZFzTE2VT9Mg MXXpcoR2[2W|IHPlcIwh\GWjdHigd4lodmmoaXPhcpRtgSCrbjDhJJZmenlibH;3JINwdmOnboTyZZRqd25? M1XFbVI2ODd6ME[0
HT1080 MXzGeY5kfGmxbjDBd5NigQ>? M1vkeFAvODByMT2xNFAh|ryP MXqxMVI1KGh? MomxSG1UV8Li MnXybY5lfWOnczDwMZA2Oyi|ZYKxOUkhcW5iYn;0bEB1cW2nLTDhcoQh[2:wY3XueJJifGmxbj3k[ZBmdmSnboSgcYFvdmW{ Ml7uNlUxPzhyNkS=
HT1080 MmPQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mm\vNE4xODBzLUGwNEDPxE1? M{Tkc|I1KGh? MnzUSG1UV8Li Mn3TZ4F2e2W|IHHuJIlv[3KnYYPlJIlvKHSqZTDueY1j\XJib3[gZ4VtdHNiaX6gS|IwVSxid3jpcIUh\GWlcnXhd4lv\yCVIHHu[EBIOSCyaHHz[UBk\Wyucx?= NFXad4kzPTB5OEC2OC=>
HD-MY-Z M{XRc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXWyOE81QC95MjDo NUO2O5ljUUN3MP-8olExOCEQvF2= MoPyNlUxPDh{M{[=
DOHH-2 MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1jmVlI1KGh? Mo\vTWM2OO,:nkGwNEDPxE1? M3K4VFI2ODR6MkO2
DOHH-2 MonnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXe0PEBp NYrHPHJtUUN3ME2xPU46yqEQvF2= MV6yOVA1QDJ|Nh?=
DOHH-2 NWjj[GYyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MV:3NkBp MlnxTWM2OD13wrFOwG0> MW[yOVA1QDJ|Nh?=
REH NGDyOoVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFjpOJczPCCq NYjjS2tSUUN3ME2wMlAzP8LizszN NIX3c4QzPTB2OEKzOi=>
REH NXfK[YE4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGnLOIg1QCCq MnjFTWM2OD1yLkCxOOKh|ryP NVizbFFiOjVyNEiyN|Y>
REH NVr5PIhRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVO3NkBp NVW4fHRMUUN3ME2wMlAyPcLizszN MljVNlUxPDh{M{[=
HH NUTOWplIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{D1cVI1KGh? MV3JR|UxRTFyND63xsDPxE1? M3v4WFI2ODR6MkO2
HH NVLMb2tpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4PWblQ5KGh? MY\JR|UxRTR6LkdCpO69VQ>? MWiyOVA1QDJ|Nh?=
HH MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXH3RoIxPzJiaB?= NHjQNlBKSzVyPUG0MlfDqM7:TR?= NYTNPZM1OjVyNEiyN|Y>
HuT-78 M3j3bmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVWyOEBp NUX4O|d5UUN3ME25MlPDqM7:TR?= NVvJZZFXOjVyNEiyN|Y>
HuT-78 NXLsWVBKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoXhOFghcA>? NISxPWZKSzVyPUSuN:Kh|ryP NVT6c2NqOjVyNEiyN|Y>
HuT-78 NYTON2JvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4\JXlczKGh? M3z0PWlEPTB;ND6yxsDPxE1? MkfsNlUxPDh{M{[=
OPM-2 M171c2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M371fVI1KGh? NVy2d5pDUUN3ME2yOE4yyqEQvF2= MonWNlUxPDh{M{[=
OPM-2 NHvwPXRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYizcpF6PDhiaB?= MYjJR|UxRTUEoN88US=> Mm\sNlUxPDh{M{[=
OPM-2 MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYe3NkBp NGGzZVJKSzVyPUGuN:Kh|ryP M3rnblI2ODR6MkO2
RPMI-8226 M33jUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXuyOEBp Ml3KTWM2OD1zME[uOuKh|ryP NF\sdoozPTB2OEKzOi=>
RPMI-8226 MlLJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXHtW3UxPDhiaB?= MlvwTWM2OD17MT6xxsDPxE1? NUXPcYF2OjVyNEiyN|Y>
RPMI-8226 MnTVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3G3ZVczKGh? MUHJR|UxRTF2LkpCpO69VQ>? MXiyOVA1QDJ|Nh?=
U-266 NV;NOZpkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWmyOEBp NWj0PXpTUUN3ME24Ok4zyqEQvF2= MVWyOVA1QDJ|Nh?=
U-266 NEDuN|dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NX7rN3E{PDhiaB?= MWnJR|UxRTZ6LkVCpO69VQ>? NG\PTGUzPTB2OEKzOi=>
U-266 NHqzb2NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHvrT5o4OiCq M1[2dGlEPTB;MkeuOOKh|ryP NHfJTG4zPTB2OEKzOi=>
Kelly MlfUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYP3UYs3OC1zMDFOwG0> NYH2cm9xPzMEoHi= MYDJR|UxRTFwNUG4xsDPxE1? NUHvU5VSOjVyMEi5NFA>
SH-SY5Y  MoXYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYWwMVExKM7:TR?= NEnTTWU4OsLiaB?= M3jicWlEPTB;MD63OVTDqM7:TdMg M2rNUlI2ODB6OUCw
SK-N-AS NYXEO4dFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2DnPVAuOTBizszN MYS3NuKhcA>? Ml;tTWM2OD1zLkexNuKh|ryPwrC= MYmyOVAxQDlyMB?=
SK-N-DZ NULa[lJOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{W1T|AuOTBizszN MWe3NuKhcA>? MnfGTWM2OD13LkS4OeKh|ryP MW[yOVAxQDlyMB?=
HepG2 NG\EXlhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NG\GTnI1QMLiaB?= NETNe|FFVVORwrC= MXvJR|UxRTF|Lk[1xsDDucLiMD65NuKh|ryP MUSyOFk6PjF|Nh?=
A549 MnzwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mn3ROFjDqGh? M4DG[GROW00EoB?= MljWTWM2OD1{NEGuPeKhyrIEoEOxMlI{yqEQvF2= MX[yOFk6PjF|Nh?=
MCF7 NGnCRVZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHnpNWI1QMLiaB?= MX\EUXNQyqB? M3LWbGlEPTB;OEGuNFnDqMLzwrCxOE4zOcLizszN M3\hVlI1QTl4MUO2
HL-60  Mn73S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnLQO|LDqGh? MkjuTWM2OD1yLkGy5qCG|ryP NXfuN|h2OjR7OUOwNVQ>
HL-60[R] MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlTtO|LDqGh? NGjIWHRKSzVyPUOuNVLjiIYQvF2= NYTJW|ZsOjR7OUOwNVQ>
MIAPACA MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnW4S2k2OD1zLkOgxtEhOC5yMzFOwG0> M4HMOVI1QTV|OEKx
MCF-7 MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHPmfYNIUTVyPUCuNlUhyrFiMD6xJO69VQ>? NYPoRW9LOjR7NUO4NlE>
HeLa MlrUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4X0cWdKPTB;MD62OEDDuSByLkSg{txO M{HNPVI1QTV|OEKx
MO59K  MnrZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYq3JIQ> MofUTWM2OD1yLkG35qCG|ryP NUfFcZp5OjR7NUO1OlE>
MO59J MkXQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NH\CVnI4KGR? MX3JR|UxRTBwMfMAie69VQ>? NUT0[lFWOjR7NUO1OlE>
ME 180 M3vxNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYm0POKhcMLi NUXkcI12UUN3ME24MlnDqMLzwrCwMlPjiIYQvF2= NEfCW28zPDl3M{CyOy=>
MCF-7 NEnwe2VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWHTcXloPDkEoHlCpC=> M1fE[mlEPTB;MkOuPUDDuSByLkRihKXPxE1? NGD0WWEzPDl3M{CyOy=>
HeLa MlPrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXG0POKhcMLi MXjJR|UxRTRwN{GgxtEhOS524pEF{txO MoXiNlQ6PTNyMke=
MDA-MB-453 NFXUbplIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYnScGpMPDkEoHlCpC=> NXLQRVhsUUN3ME2xNk42KMLzIECuPFXjiIYQvF2= M4Lo[lI1QTV|MEK3
MDA-MB-231 MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFjW[3c1QMLiaNMg MlHiTWM2OD1{ND6yNkDDuSB{Lkm05qCG|ryP NY\1UVRCOjR7NUOwNlc>
PC-3 NXXocnNMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoW0OFjDqGkEoB?= MmrKTWM2OD1zND60JOKyKDNwMkRihKXPxE1? M2HnOVI1QTV|MEK3
HT-29 NXzhO5I3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NX;pbmRRPDkEoHlCpC=> NXLHUYxIUUN3ME2yNU41PSEEsTCzMlg46oDHzszN MVyyOFk2OzB{Nx?=
BGC-823 MkPaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmnmOFjDqGkEoB?= MWjJR|UxRTR|Lke0JOKyKDVwMURihKXPxE1? NX\1W4R5OjR5OUO4O|c>
HeLa NYTPNXBxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3\yWFQ5yqCqwrC= MmPZTWM2OD1{MEmuPVAhyrFiMUOuOFIh6oDHzszN NFfGWGEzPDd7M{i3Oy=>
A549 NILzU2FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4W2TlQ5yqCqwrC= NX\meJpYUUN3ME2xN|kvPTRiwsGgO{4xPeLChd88US=> NFj0XYYzPDd7M{i3Oy=>
HK-2 NIPFO2JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFXGWXg1QMLiaNMg M{nZRmlEPTB;OT6xO{DDuSBzLkW45qCG|ryP NE\2XFQzPDd7M{i3Oy=>

... Click to View More Cell Line Experimental Data

Assay
Methods Test Index PMID
Western blot
p53 / p-p53 / Acetyl-p53 / TF-IIB; 

PubMed: 23800173     


Western blotting analysis of p53 levels and the indicated p53 post-translational modifications in the nucleus and cytoplasm of U-2 OS cells treated with no drug, 1 μmol/l etoposide (treated for 24 hours) and 100 μmol/l etoposide (treated for 12 hours), re䲧疝Ỵ疞㧀疜膉痘 瘿삨ՂᾰƌՂĀ 㺣痖帉痖Ѐ瑖堘𢡄빢᎒ՂĀ鑸᎒彿堙奋堙巫堙᎒ﻺ᎒彿堙ﻮ᎒塚堙ﻺ᎒ꍈ堞빢᎒學堙漸堞圔堙빢᎒圞堙圭堙𢡄玚Wᾰƌ ᾰƌ戤瘯Ɖ뙠ෆ䐺痖暼瘿뙠ෆᾰƌ 뙠ෆÐ㺣

p53 / p21 / c-Myc / PARP ; 

PubMed: 20212154     


Myc is repressed at the posttranscriptional level following etoposide treatment. HEK293 cells were treated with etoposide at the indicated concentrations for 24 h. Parallel samples were taken for western and northern analysis as indicated. 

23800173 20212154
Immunofluorescence
COX IV; 

PubMed: 29221178     


Panel 1 (untreated) depicts the mitochondrial distribution by visualizing the expression of Cox IV in U87(WT) cells. Panel 2 (etoposide treated) represents the distribution of mitochondria in U87(RETO) cells after 10 days of drug exposure as visualized by䲧疝Ỵ疞㧀疜膉痘 瘿삨ՂᾰƌՂĀ 㺣痖帉痖Ѐ瑖堘𢡄빢᎒ՂĀ鑸᎒彿堙奋堙巫堙᎒ﻺ᎒彿堙ﻮ᎒塚堙ﻺ᎒ꍈ堞빢᎒學堙漸堞圔堙빢᎒圞堙圭堙𢡄玚Wᾰƌ ᾰƌ戤瘯Ɖ

γH2AX / pATM ; 

PubMed: 19858003     


HeLa cells were treated with vehicle (Ctl), 6 Gy IR (IR) or 25 μM etoposide (ETO). Co-localization (yellow signal in the overlay (OL)) of gH2AX (red) and pATM (green). Scale bar = 20 μm.

MDC1; 

PubMed: 19858003     


HeLa cells were treated with vehicle (Ctl), 6 Gy IR (IR) or 25 μM etoposide (ETO). Co-localization of gH2AX with MDC1.

pDNA-PKcs; 

PubMed: 19858003     


HeLa cells were treated with vehicle (Ctl), 6 Gy IR (IR) or 25 μM etoposide (ETO). Co-localization of gH2AX with pDNA-PK.

p53; 

PubMed: 27515249     


p53 localization in untreated and 12-h etoposide treated CD41+ MK cells. Cells were stained with anti-p53 antibody. TOTO-3 was used to stain the nucleus. Scale bar=20 μm.

YAP; 

PubMed: 27515249     


(D) YAP localization in untreated CD41+MK cells and CD41+ MK cells treated by 10 μM etoposide for five hours on day 10 of culture. Cells were stained with anti-YAP antibody. DAPI was used to stain the nucleus. Cells (150) were counted and categorized acco䲧疝Ỵ疞㧀疜膉痘 瘿�෋ᾰƌ෋à 㺣痖帉痖Ѐ瑖堘𢡄빢᎒෋à鑸᎒彿堙奋堙巫堙᎒ﻺ᎒彿堙ﻮ᎒塚堙ﻺ᎒ꍈ堞빢᎒學堙漸堞圔堙빢᎒圞堙圭堙𢡄玚Wᾰƌ ᾰƌ戤瘯Ɖ삨Ղ䐺痖暼瘿삨Ղᾰƌ 삨ՂÐ㺣痖삨Ղ€𢡄사Ղ€䀷痗사Ղ౴사Ղ㵶痗사Ղ뺖᎒泌Itemセ᎒Count﫨呂샜Ղ

29221178 19858003 27515249
Growth inhibition assay
Cell viability ; 

PubMed: 22615609     


Effect of etoposide on HEK293 cell viability. Cells were seeded at 104 in 96-well plates and treated with etoposide (50,100,150 and 200µM) for 24 hrs and compared to nontreated cells (control). At the end of treatment period, cell viability was measured u䲧疝Ỵ疞㧀疜膉痘 瘿삨ՂᾰƌՂĀ 㺣痖帉痖Ѐ瑖堘𢡄빢᎒

22615609
In vivo Etoposide administrated as a single agent is found to been ineffective in many xenografts growth, such as Heterotransplanted Hepatoblastoma NMHB1, and NMHB 2, [6] human neuroblastoma xenograft, [7] and human gastrointestinal cancer xenograft, [8] while the dose of 10 mg/kg i.p. Etoposide inhibits murine angiosarcoma cell ISOS-1 tumors in 36% of controls. [2] Etoposide induces tumor immunity in Lewis lung cancer. A single administration of 50 mg/kg Etoposide i.p., induces a 60% survival of C57B1/6 mice injected with Lewis lung cancer cell (3LL) over 60 days. About 40% of these surviving mice reject a subsequent challenge with 3LL, while none of control mice survive beyond 30 days. 3LL cells which have survived an 90% lethal concentration of Etoposide in vitro kill 75% of recipient mice, but 60% surviving mice reject challenge with 3LL. Splenocytes harvested from tumor rejecting mice protect naive mice injected with 3LL. [9]

Protocol

Kinase Assay:[5]
- Collapse

Topoisomerase II activity assay:

Nuclear extracts are prepared, and nuclei are isolated. The activity of topoisomerase II is calculated from the percentage of decatenation obtained. Tritiated kinoplast DNA (KDNA 0.22 μg) is used as a substrate. Etoposide and topoisomerase II are incubated for 30 min at 37 ℃ and are stopped with 1% sodium dodecyl sulfate (SDS) and proteinase K (100 μg/mL). The percentages of decatenation and inhibition of topoisomerase II by Etoposide are obtained.
Cell Research:[5]
- Collapse
  • Cell lines: Human glioma cell lines CL5
  • Concentrations: 80 μg/mL
  • Incubation Time: 1 hour
  • Method: After the Etoposide treatment, cells are removed from the dish with phosphate-buffered saline (PBS) containing 0.03% trypsin and 0.27 mM ethylenediaminetetraacetic acid (EDTA) and are diluted into culture dishes in appropriate numbers to yield between 20 and 200 colonies. After 12 days, cultures are fixed with methanol-acetic acid, stained with crystal violet, and scored for colonies containing more than 50 cells. The standard errors are typically less than 15% of the mean value unless otherwise stated.
    (Only for Reference)
Animal Research:[2]
- Collapse
  • Animal Models: Murine angiosarcoma xenografts ISOS-1
  • Formulation: Saline
  • Dosages: 10 mg/kg
  • Administration: i.p. every day for 5 days from day 7
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 100 mg/mL (169.9 mM)
Water Insoluble
Ethanol Insoluble
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
5% DMSO+40% PEG 300+5% Tween 80+ddH2O
For best results, use promptly after mixing.
15mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 588.56
Formula

C29H32O13

CAS No. 33419-42-0
Storage powder
in solvent
Synonyms VP-16, VP-16213

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment interventions Conditions Sponsor/Collaborators Start Date Phases
NCT03264131 Recruiting Drug: Brentuximab Vedotin|Drug: CHEP Lymphoma|Adult T-Cell Leukemia/Lymphoma|Lymphatic Diseases UNC Lineberger Comprehensive Cancer Center|Seattle Genetics Inc. October 15 2018 Phase 2

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Frequently Asked Questions

  • Question 1:

    Regarding the Etoposide S1225, do you have any data of the inhibition sepcificity of this product? It will inhibit other enzymes other than TOP2A?

  • Answer:

    According to the available published data, the inhibition of Etoposide is specific to TOP2A. But there're also two papers showing that Etoposide could inhibit the p34cdc2 Kinase Activity: 1. http://cancerres.aacrjournals.org/content/52/7/1817.short ; 2. http://cancerres.aacrjournals.org/content/50/12/3761.short.

Topoisomerase Signaling Pathway Map

Related Topoisomerase Products

Tags: buy Etoposide | Etoposide supplier | purchase Etoposide | Etoposide cost | Etoposide manufacturer | order Etoposide | Etoposide distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID